MYCOF - Mydecine Announces Filing of Audited and Q1 Financial Statements
(TheNewswire)
Vancouver, British Columbia, July 5, 2024— TheNewswire – MydecineInnovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC:MYCOF) (AQSE: MYIG) is pleased to confirm that further to its newsrelease dated June 13, 2024, the Company has filed on SEDAR+ itsaudited financial statements, accompanyingmanagement discussion and analysis and related CEO and CFOcertifications for the period ended December 31, 2023 (the" AnnualFilings ") and its interim Q1 financialstatements, accompanying management discussion and analysis andrelated CEO and CFO certifications for the period ended March 31, 2024(the " QuarterlyFilings ") . The Annual Filings and Quarterly Filings can beobtained on the Company's SEDAR+ profile at www.sedarplus.ca .
The Directors of Mydecine take responsibility for thisannouncement.
This announcement contains inside information for thepurposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 asit forms part of UK domestic law by virtue of the European Union(Withdrawal) Act 2018 ("MAR"), and is disclosed inaccordance with the Company's obligations under Article 17 ofMAR.
On behalf of the Board of Directors,
MYDECINE INNOVATIONS GROUP INC.
Joshua Bartch
Chief Executive Officer
AQSE Corporate Advisor
Novum Securities Limited Tel:+44 (0)207 399 9400
David Coffman/ George Duxberry
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a biotechnologycompany developing the next generation of innovative medications andtherapies to address mental health disorders such as nicotineaddiction and posttraumatic stress disorder (PTSD). The core strategyblends advanced technology with an elaborate infrastructure for drugdiscovery and development. Mydecine's dedicated multinational teamconstantly develops new paths for breakthrough treatment solutions inareas with considerable unmet needs. By collaborating with some of theworld's leading specialists, the Company aspires to responsibly speedup the development of breakthrough medications to provide patientswith safer and more effective treatment solutions. At the same time,Mydecine's approach focuses on the next generation of psychedelicmedicine by creating innovative compounds with unmatched therapeuticpotential through its clinical trial efforts with worldclassscientific and regulatory expertise.
Learn more at: https://www.mydecine.com/ and follow thecompany on Twitter, LinkedIn, YouTube, and Instagram.
Forward-looking Information Statement
This news release may containcertain “forward-looking statements” and “forward-lookinginformation” within the meaning of applicable Canadian and UnitedStates securities laws. When used in this news release, the words“anticipate”, “believe”, “estimate”, “expect”,“target, “plan”, “forecast”, “may”, “schedule” andother similar words or expressions identify forward-looking statementsor information. These forward-looking statements or information mayrelate to the anticipated timing for the filing of the Annual Filings, and other factors orinformation. Such statements represent the Company’s current viewswith respect to future events and are necessarily based upon a numberof assumptions and estimates that, while considered reasonable by theCompany, are inherently subject to significant business, economic,competitive, political and social risks, contingencies anduncertainties. Many factors, both known and unknown, could causeresults, performance or achievements to be materially different fromthe results, performance or achievements that are or may be expressedor implied by such forward-looking statements. The Company does notintend, and does not assume any obligation, to update theseforward-looking statements or information to reflect changes inassumptions or changes in circumstances or any other events affectionssuch statements and information other than as required by applicablelaws, rules and regulations
NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDERHAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OFTHIS RELEASE.
Copyright (c) 2024 TheNewswire - All rights reserved.